tickrz reports
Pfizer Inc (PFE)
Healthcare | Drugs
36.60  0.16%
PFE vs DRUGS SECTOR & S&P 500
VALUATION
PFESECTORS&P 500
P/E RATIO22.540.521.12
EV/EBITDA RATIO13.11133.412.66
P/S RATIO4.216.52.25
P/B RATIO3.637.73.45
QUALITY
RETURN ON EQUITY15.79%15.79%13.64%
RETURN ON CAPITAL12.55%19.38%10.09%
NET MARGIN13.63%14.46%9.73%
DIVIDEND ANALYSIS
DIVIDEND YIELD
3.5%
PAYOUT RATIO76.89%
3 YR DIVIDEND GROWTH7.57%
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY72%
INTEREST COVERAGE10.9x
CURRENT RATIO1.43
GROWTH
5 YR EPS GROWTH1.13%
5 YR SPS GROWTH-4.14%
5 YR BPS GROWTH-1.99%
Pfizer Inc News
Will Amgen (AMGN) Continue to Tread Growth Path This Year?
Amgen Inc s AMGN stock was up 19 in 2017 which compared favorably with a gain of 2 8 recorded by the industry Last year s share price surge was supported by a series of positive news including promising data from several pivotal studies and rapid progress with its pipeline and
January 16, 17:12:26 UTC

How Teva Pharmaceutical Plans to Optimize Global Generics
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?
January 16, 12:31:24 UTC

Foundation Medicine, Pfizer Enter Into Broad Tie-up For Companion Diagnostics
Foundation Medicine, Pfizer Enter Into Broad Tie-up For Companion Diagnostics
January 16, 07:18:00 UTC

The Race To Find A Treatment For NASH
The Race To Find A Treatment For NASH
January 16, 01:03:00 UTC

Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
GlaxoSmithKline plc GSK received approval from the FDA s Center for Biologics Evaluation and Research for the label expansion of influenza vaccine FluarixQuadrivalent The vaccine has been approved for infants six months or older 160 The vaccine at present is approved for
January 15, 15:11:04 UTC

Teva Pharmaceutical Focusing on Per Product Operating Profits
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.
January 15, 14:02:42 UTC

Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.
January 15, 12:34:02 UTC

Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Some achievements are hard to top Alnylam Pharmaceuticals NASDAQ ALNY for example saw its stock price soar 249 in 2017 That s not an easy feat to pull off in one year much less to do it again But will 2018 be Alnylam s best year yet In terms of stock performance I
January 14, 15:07:49 UTC

5 Biotech Stocks That Could Be Bought Out in 2018
Biotechnology merger and acquisition activity could get a booster shot now that U S tax reform is cutting corporate tax rates and allowing companies to repatriate cash that s been piling up overseas We ll have to wait and see if tax reform sparks biotech M amp A in 2018 but if it
January 14, 15:07:03 UTC

5 Biotech Stocks That Could Be Bought Out in 2018
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
January 14, 14:00:00 UTC

Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride
At least it's on the upswing.
January 13, 03:08:00 UTC

After Hours Most Active for Jan 12, 2018 : F, GE, CLNS, S, VIPS, QQQ, PFE, CTRP, CELG, CENX, CSCO, FB
The NASDAQ 100 After Hours Indicator is up 1 59 to 6 760 13 The total After hours volume is currently 39 527 993 shares traded The following are the most active stocks for the after hours session Ford Motor Company F is 0 02 at 13 21 with 4 236 409 shares
January 12, 22:04:33 UTC

Here's another reason to get more bullish on stocks: NYSE trader
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the markets as earnings season kicks off in earnest.
January 12, 19:49:53 UTC

Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.
January 12, 17:50:02 UTC


Pfizer Inc (PFE)
Healthcare | Drugs
36.60  0.16%

Will Amgen (AMGN) Continue to Tread Growth Path This Year?
Amgen Inc s AMGN stock was up 19 in 2017 which compared favorably with a gain of 2 8 recorded by the industry Last year s share price surge was supported by a series of positive news including promising data from several pivotal studies and rapid progress with its pipeline and
January 16, 17:12:26 UTC

How Teva Pharmaceutical Plans to Optimize Global Generics
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?
January 16, 12:31:24 UTC

Foundation Medicine, Pfizer Enter Into Broad Tie-up For Companion Diagnostics
Foundation Medicine, Pfizer Enter Into Broad Tie-up For Companion Diagnostics
January 16, 07:18:00 UTC

The Race To Find A Treatment For NASH
The Race To Find A Treatment For NASH
January 16, 01:03:00 UTC

Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
GlaxoSmithKline plc GSK received approval from the FDA s Center for Biologics Evaluation and Research for the label expansion of influenza vaccine FluarixQuadrivalent The vaccine has been approved for infants six months or older 160 The vaccine at present is approved for
January 15, 15:11:04 UTC

Teva Pharmaceutical Focusing on Per Product Operating Profits
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.
January 15, 14:02:42 UTC

Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.
January 15, 12:34:02 UTC

Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
Some achievements are hard to top Alnylam Pharmaceuticals NASDAQ ALNY for example saw its stock price soar 249 in 2017 That s not an easy feat to pull off in one year much less to do it again But will 2018 be Alnylam s best year yet In terms of stock performance I
January 14, 15:07:49 UTC

5 Biotech Stocks That Could Be Bought Out in 2018
Biotechnology merger and acquisition activity could get a booster shot now that U S tax reform is cutting corporate tax rates and allowing companies to repatriate cash that s been piling up overseas We ll have to wait and see if tax reform sparks biotech M amp A in 2018 but if it
January 14, 15:07:03 UTC

5 Biotech Stocks That Could Be Bought Out in 2018
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
January 14, 14:00:00 UTC

Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride
At least it's on the upswing.
January 13, 03:08:00 UTC

After Hours Most Active for Jan 12, 2018 : F, GE, CLNS, S, VIPS, QQQ, PFE, CTRP, CELG, CENX, CSCO, FB
The NASDAQ 100 After Hours Indicator is up 1 59 to 6 760 13 The total After hours volume is currently 39 527 993 shares traded The following are the most active stocks for the after hours session Ford Motor Company F is 0 02 at 13 21 with 4 236 409 shares
January 12, 22:04:33 UTC

Here's another reason to get more bullish on stocks: NYSE trader
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the markets as earnings season kicks off in earnest.
January 12, 19:49:53 UTC

Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.
January 12, 17:50:02 UTC